<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9697">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02980705</url>
  </required_header>
  <id_info>
    <org_study_id>CLR_16_22</org_study_id>
    <nct_id>NCT02980705</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of SUNPG1622</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Pharma Global FZE</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Pharma Global FZE</source>
  <brief_summary>
    <textblock>
      This is a randomized, double-Blind, placebo-controlled Phase 2a study to evaluate the
      efficacy and safety of SUNPG1622.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>February 2017</start_date>
  <completion_date type="Anticipated">September 2019</completion_date>
  <primary_completion_date type="Anticipated">September 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects who achieve improvement of ≥ 40% and absolute improvement of ≥ 20 units from baseline in a visual analog scale (0 [no disease activity]-100 [high disease activity])</measure>
    <time_frame>Week 24</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who achieve improvement of ≥ 40% and absolute improvement of ≥ 20 units from baseline in a visual analog scale (0 [no disease activity]-100 [high disease activity])</measure>
    <time_frame>Week 52</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Active Ankylosing Spondylitis or Non-Radiographic Axial Spondyloarthritis</condition>
  <arm_group>
    <arm_group_label>SUNPG1622 I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SUNPG1622 I dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SUNPG1622 I dose</intervention_name>
    <arm_group_label>SUNPG1622 I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo dose</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject has provided informed written consent

          -  Subject is ≥ 18 years of age at time of Screening

          -  Subject must be on a stable dose of NSAID for ≥ 2 weeks prior to initiation of
             investigational product

          -  Subject has a negative test for TB within 4 weeks before initiating IMP

        Exclusion Criteria:

          -  Subjects with known diagnosis of fibromyalgia or complex regional pain syndromes

          -  Active uveitis or symptomatic inflammatory bowel disease requiring therapy at
             screening

          -  Radiographic evidence of total ankylosis of the spine

          -  Subject has a planned surgical intervention between Baseline and the Week 24
             evaluation for a pre-treatment condition
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Shravanti Bhowmik, MD</last_name>
    <phone>912266455645</phone>
    <email>shravanti.bhowmik@sparcmail.com</email>
  </overall_contact>
  <verification_date>November 2016</verification_date>
  <lastchanged_date>November 30, 2016</lastchanged_date>
  <firstreceived_date>November 30, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Spondylitis</mesh_term>
    <mesh_term>Spondylitis, Ankylosing</mesh_term>
    <mesh_term>Spondylarthritis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
